Sonochemiluminescence in an aqueous solution of Ru(bpy)3Cl2

Шарипов, Г. Л.; Abdrakhmanov, A. M.; Gareev, B.M.; Yakshembetova, L.R.

doi:10.1016/j.ultsonch.2017.12.013

Cited by 22 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The anticancer activity of 4 was primarily due to the mitochondrial damage of tumor cells by 1 O 2 and CO, as was evident from the change in mitochondrial transmembrane potential. [49] The in-vivo anticancer results with 2 and 4 on 4T1 tumor-bearing mice were consistent with the in-vitro study, displaying the significant tumor growth inhibition effect of 2/4 + US. Complex 2 remarkably inhibited tumor growth by ca.…”

supporting

confidence: 82%

Metal Complexes for Cancer Sonodynamic Therapy

et al. 2022

View full text Add to dashboard Cite

Sonodynamic therapy (SDT) for cancer treatment is gaining attention owing to its non‐invasive property and ultrasound‘s (US) deep tissue penetration ability. In SDT, US activates the sonosensitizer at the target deep‐seated tumors to generate reactive oxygen species (ROS), which ultimately damage tumors. However, drawbacks such as insufficient ROS production, aggregation of sonosensitizer, off‐target side effects, etc., of the current organic/nanomaterial‐based sonosensitizers limit the effectiveness of cancer SDT. Very recently, metal complexes with tunable physiochemical properties (such as sonostability, HOMO to LUMO energy gap, ROS generation ability, aqueous solubility, emission, etc.) have been devised as effective sonosensitizers, which could overcome the limitations of organic/nanomaterial‐based sonosensitizers. This concept introduces all the reported metal‐based sonosensitizers and delineates the prospects of metal complexes in cancer sonodynamic therapy. This new concept of metal‐based sonosensitizer can deliver next‐generation cancer drugs.

show abstract

supporting

confidence: 82%

Metal Complexes for Cancer Sonodynamic Therapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Moreover, radical products of sonolysis of water can also excite [Ru(bpy) 3 ] 2+ . The sonochemiluminescence spectra of [Ru(bpy) 3 ] 2+ was recorded by US irradiation of argon saturated aqueous solutions of [Ru(bpy) 3 ] 2+ 38 – 40 .…”

Section: Introductionmentioning

confidence: 99%

A highly potent ruthenium(II)-sonosensitizer and sonocatalyst for in vivo sonotherapy

et al. 2021

View full text Add to dashboard Cite

As a basic structure of most polypyridinal metal complexes, [Ru(bpy)3]2+, has the advantages of simple structure, facile synthesis and high yield, which has great potential for scientific research and application. However, sonodynamic therapy (SDT) performance of [Ru(bpy)3]2+ has not been investigated so far. SDT can overcome the tissue-penetration and phototoxicity problems compared to photodynamic therapy. Here, we report that [Ru(bpy)3]2+ is a highly potent sonosensitizer and sonocatalyst for sonotherapy in vitro and in vivo. [Ru(bpy)3]2+ can produce singlet oxygen (1O2) and sono-oxidize endogenous 1,4-dihydronicotinamide adenine dinucleotide (NADH) under ultrasound (US) stimulation in cancer cells. Furthermore, [Ru(bpy)3]2+ enables effective destruction of mice tumors, and the therapeutic effect can reach deep tissues over 10 cm under US irradiation. This work paves a way for polypyridinal metal complexes to be applied to the noninvasive precise sonotherapy of cancer.

show abstract

“…[19] They chose this complex due to its very low difference in energy between LUMO and HOMO, and the water's sono-luminescence is reported to be enough for [Ru(bpy) 3 ] 2 + excitation. [21,22] Interestingly, they have Mechanism of sonodynamic therapy by [Ru(bpy) 3 ] 2 + . [19] observed [Ru(bpy) 3 ] 2 + induced singlet oxygen ( 1 O 2 ) generation in aqueous solution on US irradiation (0.3 W/cm 2 , 3 MHz), indicating that [Ru(bpy) 3 ] 2 + can be used as an efficient sonosensitizer.…”

mentioning

confidence: 99%

Sonodynamic Therapy with Metal Complexes: A New Promise in Cancer Therapy

et al. 2021

View full text Add to dashboard Cite

In recent years, to overcome the problem of low tissue penetration power of light in photodynamic therapy (PDT), sonodynamic therapy (SDT) with ultrasound (US) as the drug stimulus has emerged as a potential alternative to PDT. The significantly higher tissue penetration capacity of US is reported to allow the treatment of deep‐seated tumours. In general, organic molecules and nanomaterials dominate as the sonosensitizers in this area of research, and the potential of metal complexes in SDT is not yet well explored. In this highlight, we have summarized two recent literature reports in which researchers have explored the efficiency of metal complexes as sonosensitizers for the first time. These reports indicate the high potential of metal complexes in SDT.

show abstract

Sonochemiluminescence in an aqueous solution of Ru(bpy)3Cl2

Cited by 22 publications

References 29 publications

Metal Complexes for Cancer Sonodynamic Therapy

Metal Complexes for Cancer Sonodynamic Therapy

A highly potent ruthenium(II)-sonosensitizer and sonocatalyst for in vivo sonotherapy

Sonodynamic Therapy with Metal Complexes: A New Promise in Cancer Therapy

Contact Info

Product

Resources

About